Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
MRD-positive AML Clinical Study
ClinicalTrials.gov study NCT07131059. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02610062. IPD Sharing: NO. Countries: 2. Publications: 0.
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
ClinicalTrials.gov study NCT05330377. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
ClinicalTrials.gov study NCT06563804. IPD Sharing: YES. Countries: 6. Publications: 0.
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
ClinicalTrials.gov study NCT04284228. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
ClinicalTrials.gov study NCT06783790. IPD Sharing: NO. Countries: 1. Publications: 0.
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
ClinicalTrials.gov study NCT05703126. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
ClinicalTrials.gov study NCT05986240. IPD Sharing: NO. Countries: 1. Publications: 0.
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
ClinicalTrials.gov study NCT00943943. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)
ClinicalTrials.gov study NCT03801005. IPD Sharing: Not stated. Countries: 1. Publications: 0.
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
ClinicalTrials.gov study NCT04713956. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT02141477. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT02715011. IPD Sharing: Not stated. Countries: 2. Publications: 0.
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)
ClinicalTrials.gov study NCT01592266. IPD Sharing: Not stated. Countries: 1. Publications: 0.
VA vs DA for Newly Diagnosed Hig-risk AML
ClinicalTrials.gov study NCT05939180. IPD Sharing: NO. Countries: 1. Publications: 0.
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT01145846. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT05319587. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
ClinicalTrials.gov study NCT05457010. IPD Sharing: NO. Countries: 1. Publications: 0.
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
ClinicalTrials.gov study NCT06744556. IPD Sharing: NO. Countries: 1. Publications: 0.
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
ClinicalTrials.gov study NCT01898663. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.